Navigating Emerging Therapeutics: How Mikart Supports Cannabinoid And Psilocybin Drug Development

As interest in plant‑derived and alternative therapies grows, cannabinoids and psilocybin have moved into the pharmaceutical spotlight. Once associated mainly with natural wellness communities, these compounds are now the focus of significant clinical research exploring their potential to treat conditions such as chronic pain, epilepsy, anxiety, depression, and PTSD. With evolving regulations and increasing scientific validation, organizations across the U.S., Canada, Europe, and Australia are investing heavily in developing standardized, compliant, and scalable cannabinoid and psilocybin therapies.

As regulatory pathways expand—highlighted by FDA‑approved cannabinoid treatments and psilocybin programs receiving Breakthrough Therapy designation—the need for experienced CDMO partners continues to rise. Mikart is uniquely positioned to support these programs with more than 50 years of controlled‑substance manufacturing expertise. DEA‑licensed to handle Schedule I–V materials, Mikart provides secure, compliant infrastructure and deep formulation knowledge across oral solid, liquid, and alternative dosage forms.

With capabilities spanning clinical to commercial manufacturing, robust regulatory support, and a proven understanding of the complexities surrounding controlled substances, Mikart helps companies navigate development challenges and accelerate time to market. As cannabinoid and psilocybin therapy landscapes evolve, Mikart stands ready to guide innovative programs from concept to commercialization.